Le SAKK/Amgen Research Grant 2021 a été remis au professeur Markus Jörger pour le projet intitulé "Bone turnover markers in patients receiving 4-weekly versus 12-weekly denosumab in the SAKK 19/12 randomized-non-inferiority phase III trial : SAKK 96/12 Bone Turnover Markers Substudy ".
Prof. Dr. med. Roger von Moos (Jury-Präsident und SAKK Präsident ), Prof. Dr. med. Markus Jörger (Department of Oncology and Hematology, KSSG), Dr. Christian Merkle (Amgen Schweiz)
Le SAKK/Amgen Research Grant 2019 a été remis à Dr. Silvia Angori et Prof. Peter Schraml pour leur projet “Addressing the medical need for treatment of patients with papillary Renal Cell Carcinoma (pRCC) Type 2”.
Dr. Sara Christina Meyer
Universitätsspital Basel, Hämatologie
Targeting therapeutic resistance to novel JAK2 inhibitors in myeloproliferative neoplasms
Dr. Roger von Moos, Dr. Sara Christina Meyer, Dr. Christian Merkle
Dr. Cathrin Balmelli
Prof. Viviane Hess, Universitätsspital Basel, Medizinische Onkologie
Dr. Christoph Berger
Universitätsspital Basel, Biomedizinische Forschung, Immunbiologie
Impact of physical activity on adaptive and innate immune functions of patients with metastatic colorectal cancer. A translational project.
Prof. Dr. Alfred Zippelius
Medizinische Onkologie, Department für Innere Medizin, Universitätsspital Basel
Dr. Philipp Müller
Laboratory Cancer Immunology + Biology, Department Biomedizin, Universitätsspital Basel
Projet: Dissecting the Immuno-modulatory Capacities of Microtubule-Blocking Agents in Cancer Patients and Murine Tumor Models – a Novel Mechanism of Action for T-DM1
Dr. Christian Ruiz
Institut für Pathologie, Universitätsspital Basel
Projekt: Genomic analysis of flow-sorted clonal tumor populations from breast cancer patients: Genomic heterogeneity and clonal evolution
Prof. Adrian Ochsenbein
Medizinische Onkologie, Inselspital Bern
Projet: Immunogenicity of chronic myeloid leukemia stem cells
Dr. med Christoph Mamot
Medizinische Universitätsklinik, Kantonsspital Aarau
Projet: Targeting of VEGFR-3 expressing endothelial tip cells as a novel anti-angiogenic approach
Prof. Rolf Stahel
Klinik für Onkologie, Universitätsspital Zürich
Projet: Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results